Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Format:	article
Language:	EN
Published:	Dove Medical Press 2014
Subjects:	Therapeutics. Pharmacology RM1-950
Online Access:	https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea40
record_format	dspace
spelling	oai:doaj.org-article:0e4dedde10cd43628941128f1a86ea402021-12-02T06:30:52ZSingle- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]1179-1438https://doaj.org/article/0e4dedde10cd43628941128f1a86ea402014-03-01T00:00:00Zhttp://www.dovepress.com/single--and-multiple-dose-pharmacokinetics-pharmacodyncorrigendum-a16243https://doaj.org/toc/1179-1438 Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original articleCui YSong YWang JYu ZSchuster ABarrett YCFrost CDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 61-62 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
description	Cui Y, Song Y, Wang J, et al. Clinical Pharmacology: Advances and Applications. 2013;5(1):177–184.Note that on page 182, Figure 3 should be corrected as follows, with the line for mean anti-Xa activity extended through to 72 hours post dose on Day 9, and the Day 1 plasma apixaban concentration-time profile rendering error bars and symbols more visually apparent.Read the original article
format	article
author	Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C
author_facet	Cui Y Song Y Wang J Yu Z Schuster A Barrett YC Frost C
author_sort	Cui Y
title	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_short	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_full	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_fullStr	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_full_unstemmed	Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
title_sort	single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy chinese subjects [corrigendum]
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/0e4dedde10cd43628941128f1a86ea40
work_keys_str_mv	AT cuiy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT songy singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT wangj singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT yuz singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT schustera singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT barrettyc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum AT frostc singleandmultipledosepharmacokineticspharmacodynamicsandsafetyofapixabaninhealthychinesesubjectscorrigendum
_version_	1718399857549377536

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Similar Items